RecruitingNCT06836011

A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.

Studying Wild type ATTR amyloidosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Medical University of Vienna
Enrollment: 600 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (8)

Medical University of Graz, Graz, Styria, Austria
Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
Medizinische Klinik und Poliklinik I, Klinikum der Universitaet Muenchen, Ludwig-Maximilians-University, Munich, Bavaria, Germany
Department of Cardiology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Hesse, Germany
Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
Cardiologic Centre, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy
University Medical Center Utrecht, Utrecht, Netherlands

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06836011 on ClinicalTrials.gov

Other trials for Wild type ATTR amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Wild type ATTR amyloidosis →

← Back to all trials